CME Presentations

Pediatric Epilepsies



  • Kelly Knupp, MD

    Kelly Knupp, MD

    Kelly Knupp, MD

    Associate Professor of Pediatrics and Neurology

    Kelly Knupp, MD, is associate professor of pediatrics and neurology at the University of Colorado. She practices at Children’s Hospital Colorado in Aurora, where she is associate research director of the Neuroscience Institute, director of the Dravet Program, and co-interim section chief. Dr Knupp’s research interests are epileptic encephalopathies, including Dravet Syndrome. She was a founding member of the Pediatric Epilepsy Research Consortium, which focuses on developing collaborative research nationally for children with epileptic encephalopathies. Dr Knupp serves on the medical advisory boards of the Epilepsy Foundation of Colorado and the Dravet Syndrome Foundation. She received her medical degree from the University of New Mexico School of Medicine in Albuquerque.
  • Joseph Sullivan, MD

    Joseph Sullivan, MD

    Joseph Sullivan, MD

    Professor of Neurology & Pediatrics

    Joseph Sullivan, MD, is a professor of neurology and pediatrics at the University of California, San Francisco (UCSF) and director of the UCSF Pediatric Epilepsy Center of Excellence at Benioff Children’s Hospital. He completed a pediatric residency at the Ann & Robert H. Lurie Children’s Memorial Hospital of Northwestern University in Chicago, where he spent an additional year as pediatric chief resident. He completed his neurology, child neurology and epilepsy training at the Hospital of the University of Pennsylvania and at The Children’s Hospital of Philadelphia, before taking his first faculty position at UCSF in 2007. Furthermore, he has served as a principal investigator for many clinical trials in rare pediatric epilepsies.

CME Information

Global LogoPQH Logo

Lennox‐Gastaut Syndrome: Optimizing Diagnosis, Treatment, and Patient Outcomes

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders, Inc (NORD).


This activity is supported by an educational grant from Zogenix, Inc. – now a part of UCB


This activity was released on May 16, 2022 and is valid until November 16, 2022. Requests for credit must be made no later than November 16, 2022.


The educational design of this activity addresses the needs of neurologists, pediatric neurologists, pediatricians and other health care professionals (including physicians, physicians-in-training, nurses, physician assistants, nurse practitioners, pharmacists, etc.) involved and/or interested in the management of patients with severe forms of pediatric intractable epilepsy.


Lennox‐Gastaut syndrome (LGS) is a difficult‐to‐manage form of childhood onset epilepsy. LGS is particularly challenging to diagnose and treat due to its multiple seizure types, associated comorbidities, and high morbidity and mortality burden. While an early diagnosis is key to the optimal management of childhood onset epilepsy, LGS is often diagnosed late and frequently confused with other seizure types.

In this continuing medical education activity, the expert faculty will discuss the importance of an early diagnosis of LGS, when treatments are most likely to alter the clinical course of the disease and prevent poor outcomes. Expert panelists will review the current treatment armamentarium for LGS to ensure clinicians are able to select the most appropriate first‐ and second-line options for patients with LGS. In addition, faculty will explore emerging data on investigational treatments with the potential to change practice and improve outcomes for patients with Dravet syndrome and LGS.


After completing this activity, the participant should be better able to:
  • Explain the prevalence, clinical features, and importance of early diagnosis in LGS
  • Select appropriate treatments with proven efficacy and safety in LGS
  • Discuss emerging treatment options for LGS


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


ACPE Logo Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-22-003-H01-P)
This is a knowledge-based activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Kelly G. Knupp, MD, MSCS, FAES
Interim Co-Chief, Section of Child Neurology
Co-Director, Neurology Research
Associate Professor of Pediatrics and Neurology
University of Colorado, Anschutz Medical Campus
Consulting Fee: Epygenix, Zogenix, Stoke, Encoded
Contracted Research: Eisai, Zogenix, Stoke, Encoded
Joseph E. Sullivan, MD
Professor of Neurology & Pediatrics
University of California, San Francisco (UCSF)
Director, UCSF Pediatric Epilepsy Center of Excellence
Co-Director, PISCES Longitudinal Integrated Clerkship
Consulting Fee: Epilepsy Study Consortium, Encoded Therapeutics, Greenwich Biosciences, Epygenix Therapeutics, Invitae, Knopp Biosciences, Longboard, Asceneuron, Praxis, Supernus
Contracted Research: Zogenix, Stoke Therapeutics, Marinus Pharmaceuticals, Bio-pharm Solutions, Encoded Therapeutics, Xenon, Takeda
Stock Option Holder: Epygenix Therapeutics

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, RN, MSN, FNP Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Eve Wilson Nothing to disclose
Alissa Yost Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact at 877-394-1306 or at